Literature DB >> 8753678

Cardiac iodine-123 metaiodobenzylguanidine uptake in animals with diabetes mellitus and/or hypertension.

E A Dubois1, K L Kam, G A Somsen, G J Boer, K de Bruin, H D Batink, M Pfaffendorf, E A van Royen, P A van Zwieten.   

Abstract

The aim of the present study was to evaluate the use of the noradrenaline analogue iodine-123 metaiodobenzylguanidine ([123I]MIBG) for the assessment of cardiac sympathetic activity in the presence of diabetes mellitus and/or hypertension in animal models. One model used Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) rendered diabetic at 12 weeks of age by an intravenous injection of streptozotocin (STZ). The other model used lean and obese Zucker rats. In all groups basic haemodynamic values were established and animals received an intravenous injection of 50 microCi [123I]MIBG. Initial myocardial uptake and wash-out rates of [123I]MIBG were measured scintigraphically during 4 h. After sacrifice, plasma noradrenaline and left cardiac ventricular beta-adrenoceptor density was determined. The diabetic state, both in STZ-treated rats (direct induction) and in obese Zucker rats (genetic induction), appeared to induce a lower cardiac density of beta-adrenoceptors, indicative of increased sympathetic activity. Cardiac [123I]MIBG then showed increased wash-outs, thereby confirming enhanced noradrenergic activity. This parallism of results led to the conclusion that [123I]MIBG wash-out measurements could provide an excellent tool to assess cardiac sympathetic activity non-invasively. However, in hypertension (WKY vs SHR), both parameters failed to show parallelism: no changes in beta-adrenoceptor density were found, whereas [123I]MIBG wash-out rate was increased. Thus, either [123I]MIBG washout or beta-adrenoceptor density may not be a reliable parameter under all circumstances to detect changes in the release of noradrenaline. Changes in the initial uptake of [123I]MIBG were observed as well. This may be a good marker for the disappearance of cardiac innervation, but it seems not to be a good parameter for distinguishing between loss of sympathetic innervation and enhanced uptake of noradrenaline in pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8753678     DOI: 10.1007/bf01084363

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  44 in total

1.  Cardiac norepinephrine, beta-adrenoceptors, and Gi alpha-proteins in prehypertensive and hypertensive spontaneously hypertensive rats.

Authors:  M Böhm; M Castellano; M Paul; E Erdmann
Journal:  J Cardiovasc Pharmacol       Date:  1994-06       Impact factor: 3.105

2.  Inter-laboratory comparison of plasma catecholamine determinations using several different assays.

Authors:  P Hjemdahl
Journal:  Acta Physiol Scand Suppl       Date:  1984

Review 3.  Diabetes mellitus and hypertension.

Authors:  M Epstein; J R Sowers
Journal:  Hypertension       Date:  1992-05       Impact factor: 10.190

Review 4.  Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system.

Authors:  P A Daly; L Landsberg
Journal:  Diabetes Care       Date:  1991-03       Impact factor: 19.112

5.  Observations on atrial natriuretic peptide, sympathetic activity and renal Ca2+ pump in diabetic and hypertensive rats.

Authors:  A Sahai; P K Ganguly
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

6.  Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma.

Authors:  T J Mangner; M C Tobes; D W Wieland; J C Sisson; B Shapiro
Journal:  J Nucl Med       Date:  1986-01       Impact factor: 10.057

7.  The effects of sympathetic nervous system activation and psychological stress on glucose metabolism and blood pressure in subjects with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  D G Bruce; D J Chisholm; L H Storlien; E W Kraegen; G A Smythe
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

8.  Plasma concentrations of catecholamines in two strains of spontaneously hypertensive rats at different ages.

Authors:  P Ferrari; G B Picotti; E Minotti; G P Bondiolotti; A M Caravaggi; G Bianchi
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

9.  Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine.

Authors:  M Mäntysaari; J Kuikka; J Mustonen; K Tahvanainen; E Vanninen; E Länsimies; M Uusitupa
Journal:  Diabetes       Date:  1992-09       Impact factor: 9.461

10.  Streptozotocin-induced diabetes mellitus in spontaneously hypertensive rats: a pathophysiological model for the combined effects of hypertension and diabetes.

Authors:  A J Pijl; A C van der Wal; M J Mathy; K L Kam; M G Hendriks; M Pfaffendorf; P A van Zwieten
Journal:  J Pharmacol Toxicol Methods       Date:  1994-12       Impact factor: 1.950

View more
  3 in total

1.  Expression of gLTP in sympathetic ganglia of obese Zucker rats in vivo: molecular evidence.

Authors:  K H Alzoubi; A M Aleisa; K A Alkadhi
Journal:  J Mol Neurosci       Date:  2008-06-19       Impact factor: 3.444

2.  Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging.

Authors:  James T Thackeray; Rob S Beanlands; Jean N Dasilva
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-20

Review 3.  Expression and Signaling of β-Adrenoceptor Subtypes in the Diabetic Heart.

Authors:  Betul R Erdogan; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-26       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.